Pacira BioSciences Reports $179.5M Revenue in Q3 2025, Net Income Recovery

Pacira BioSciences, Inc. reported a total revenue of $179.5 million for the third quarter of 2025, reflecting a 6% increase from $168.6 million in the same period of 2024. The growth was primarily driven by a 6% rise in net product sales, which reached $178.0 million, with EXPAREL sales contributing $139.9 million, up 6% year-over-year. The company also noted a significant increase in royalty revenue, which rose 73% to $1.5 million. For the nine months ending September 30, 2025, total revenues increased by 3% to $529.5 million, compared to $513.7 million in the prior year.

In terms of profitability, Pacira reported a net income of $5.4 million for Q3 2025, a notable recovery from a net loss of $143.5 million in Q3 2024. This turnaround was attributed to reduced operating expenses, which fell to $173.2 million from $308.1 million in the previous year, largely due to the absence of a goodwill impairment charge that had significantly impacted the prior year's results. The company’s gross margin improved to 81% in Q3 2025, up from 77% in Q3 2024, driven by lower inventory reserves and improved product costs.

Strategically, Pacira has made significant moves, including the acquisition of GQ Bio Therapeutics GmbH in February 2025, which is expected to enhance its gene therapy capabilities. The company also decommissioned its 45-liter EXPAREL batch manufacturing suite in July 2025, resulting in a workforce reduction of approximately 8%. This decision is anticipated to yield annual savings of about $13 million, as the company shifts focus to larger-scale manufacturing processes that began commercial production in 2024.

Operationally, Pacira's workforce decreased to 830 employees as of September 30, 2025, down from 900 at the end of 2024. The company has also expanded its geographic reach, with its products now available in the U.S., E.U., and U.K. The adoption rates for its key products, EXPAREL and ZILRETTA, remain strong, with the latter seeing a slight increase in sales despite a decrease in kit volume due to a transition in the sales force. The company continues to invest in its product pipeline, including ongoing clinical trials for its gene therapy candidate, PCRX-201.

Looking ahead, Pacira anticipates continued growth driven by its strategic initiatives and product development efforts. The company expects to leverage its recent acquisitions and manufacturing efficiencies to enhance its market position. However, it remains cautious about potential impacts from global economic conditions, including inflation and tariffs, which could affect operational costs and product pricing. The company is committed to maintaining its focus on non-opioid pain management solutions, aiming to expand the use of its existing products while exploring new therapeutic opportunities.